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The net clinical benefit of any antithrombotic drug for the treatment of acute 
coronary syndromes (ACS) is described by its favorable effects on major outcomes 
(mortality, reinfarction, stroke) and its unfavorable effects on bleeding. Traditionally, 
with most antithrombotic therapies an increased hemorrhagic risk is accepted in order 
to achieve better efficacy. Recently, the importance of bleeding as an adverse outcome 
has received wide attention.
Major bleeding in ACS is not rare. In GRACE, the multinational registry of ACS, 
4% of patients with unstable angina, STEMI or non-STEMI had a major hemorrhage. 
In-hospital mortality was 18.6% in those patients who experienced major bleeding 
versus only 5.1% in those without such an adverse event. What is more interesting is 
the fact that the appearance of a non-fatal major bleeding event in hospital increases 
the long-term risk of death and carries a similar prognostic significance to re-infarc-
tion. The odds ratio (OR) for 6-month mortality is 5.6 for a patient with re-infarction 
in hospital and 4.5 for a patient with major hemorrhage in hospital [1].
The antithrombin drugs that are commonly used in the treatment of ACS are 
unfractionated heparin (UFH) and low molecular weight heparins (LMWH). Both 
are indirect thrombin inhibitors (requiring antithrombin-III) with anti-Xa and anti-II 
properties. Both have proved to be effective in reducing death or myocardial infarction 
in randomized clinical trials with a small and acceptable increase in major bleedings. 
Consequently they both have a class I indication in current practice guidelines [2]. 
Enoxaparin has gained popularity because of its practicality. A meta-analysis of trials 
comparing enoxaparin with UFH showed similar mortality (3 vs 3%), marginally less 
re-infarction (10.1 vs 11%), with no increase in major bleeding; RR 1.04) [3].
Two newer antithrombins have recently been tested for efficacy and safety in the 
treatment of ACS. Fondaparinux is a synthetic pentasacharide with exclusive anti-Xa 
properties. It is an indirect antithrombin (like the LMWH) with excellent bioavail-
ability, longer half life (once daily subcutaneous administration), resistance to platelet 
factor 4 and no thrombocytopenia risk. OASIS-5 randomized 20,000 patients with 
ACS to enoxaparin 1 mg/Kg twice daily or fondaparinux 2.5 mg once daily [4]. The 
composite end point of death, infarction, refractory ischemia at day  was identical 
in the two treatment groups (HR 1.01). However, major bleeding events were halved 
with fondaparinux (2.1% vs 4%; p<0.00001). At 6 months, mortality was significantly 
lower with fondaparinux (5.6% vs 6.3%; p=0.037). This reduction is mainly driven by 
the early avoidance of major bleeding events.
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Direct thrombin inhibitors have an anticoagulant effect 
against both free and clot bound thrombin, are resistant to 
plasma protein inactivation and achieve stable aPTT levels. 
Bivalirudin has been tested in patients with ACS treated with 
an early invasive strategy [5]. The three treatment arms were 
UFH (or Enoxaparin) + IIb/IIIa inhibitor, Bivalirudin + IIb/
IIIa Inhibitor and Bivalirudin alone. The composite end point 
of death, myocardial infarction and urgent revascularization 
was 7.3%, 7.7% and 7.8% respectively (ns). Major bleeding 
rates were 5.7%, 5.3% and 3% (p<0.001 for bivalirudin alone 
vs heparin +IIb/IIIa inhibitor). Similarly, less bleeding rates 
were noted in patients undergoing percutaneous coronary 
intervention (PCI) treated with bivalirudin in comparison 
with UFH+ IIb/IIIa inhibitors [6].
Both fondaparinux and bivalirudin are recommended in 
current guidelines as anthithrombin therapies in ACS patients 
with their main advantage being increased safety due to re-
duced bleeding events [2]. 
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